Who is sponsoring NCT06022055?

NCT06022055 is sponsored by Assistance Publique - Hôpitaux de Paris.

What drugs are being tested in NCT06022055?

Interventions in NCT06022055: Blood and tissue collection.

What condition does NCT06022055 study?

NCT06022055 studies Focal Drug-resistant Epilepsy.

Is NCT06022055 still recruiting?

NCT06022055 is currently recruiting now. Last updated 3 July 2025.

Last reviewed 2025-07-03 · How we verify

NCT06022055: TIPI²

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Multimodal Study of the Human Brain Epilepsy Tissue

Recruiting now NA Last updated 3 July 2025

What this trial tests

NA trial testing Blood and tissue collection in Focal Drug-resistant Epilepsy in 150 participants. Currently enrolling.

Timeline

29 February 2024

Primary endpoint
28 February 2030

28 February 2037

Quick facts

Lead sponsor	Assistance Publique - Hôpitaux de Paris
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	basic science
Enrollment	150
Start date	29 February 2024
Primary completion	28 February 2030
Estimated completion	28 February 2037
Sites	1 location across France

Drugs / interventions tested

Blood and tissue collection

Conditions studied

Focal Drug-resistant Epilepsy — all drugs for Focal Drug-resistant Epilepsy →

Sponsor

Assistance Publique - Hôpitaux de Paris — full company profile →

Who can join

18 and older, any sex, with Focal Drug-resistant Epilepsy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The TIPI2 study is a blood and tissue collection protocol to create an annotated biorepository to support research in drug-resistant epilepsy. The aim of the study will be to identify new pathophysiological pathways. For this purpose, the investigators will investigate with a multimodal approach blood and brain samples from patients undergoing a surgery for focal drug-resistant epilepsy. The adult patients will be enrolled either during the pre-surgical evaluation or right before the surgery.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Assistance Publique - Hôpitaux de Paris trials

Trials by the same sponsor.

NCT07443436 — Immunomodulatory Treatment of Interstitial Lung Disease Associated With Surfactant Related Gene Variants · Phase 2 · not yet recruiting
NCT07499492 — Red Blood Cell Transfusion to Optimize Extubation · NA · not yet recruiting
NCT07379918 — Real-life Evaluation of Endopredict® in Early HR+/HER2- Breast Cancer · recruiting
NCT07473869 — Smartphone Application for Automated Measurement of Capillary Refill Time (CRT) · not yet recruiting
NCT07505394 — Efficacy of a Prediction Model-based Algorithm to PREVENT Drug-induced Impulse Control Disorders in Parkinson's Disease · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06022055 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Assistance Publique - Hôpitaux de Paris
Last refreshed: 3 July 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06022055.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing